logo
Morning Bid: Europe Inc braces for pain from a sturdy euro

Morning Bid: Europe Inc braces for pain from a sturdy euro

Reuters6 days ago
A look at the day ahead in European and global markets from Ankur Banerjee
The incredible rise of the euro this year is sure to play a part in Europe Inc's performance as a steady but unspectacular start to the earnings season kicks up a notch with results due from the region's largest software maker SAP (SAPG.DE), opens new tab.
While tariff uncertainties linger ahead of an August 1 deadline, investors are pinning their hopes on resilient corporate earnings from Wall Street and European bellwethers to keep stocks and sentiment aloft.
Investors will parse through quarterly results for any clues on the impact trade uncertainty has had on profitability and consumer demand, with the earnings so far described by RBC Capital Markets as "fine but not fabulous".
SAP, which has been riding a boom in demand for its cloud-based offerings spurred by artificial intelligence, will report later on Tuesday as will UniCredit (CRDI.MI), opens new tab and Julius Baer (BAER.S), opens new tab.
Focus will be on just how much the euro's rise has eaten into profits of the firms in the bloc's export-reliant economy after the single currency surged 9% in the April-June quarter.
The euro is up 13% so far in the year as investors looked for alternatives to U.S. assets and to lower their dollar exposure in the wake of U.S. President Donald Trump's erratic trade policies.
SAP had predicted back in April that for every 1 cent rise in the euro, its annual revenue could decline by around 30 million euros. The euro was last at $1.1688 compared to $1.1329 at the end of April.
Earnings from luxury behemoth LVMH (LVMH.PA), opens new tab and drugmaker Roche (ROG.S), opens new tab this week will also be of interest.
Tariffs and where they are headed remain on the agenda after diplomats said the EU is exploring wide-ranging "anti-coercion" measures which would let the bloc target U.S. services or curb access to public tenders in the absence of a deal.
Trump has threatened 30% duties on imports from Europe if no agreement is signed before the August 1 deadline.
Meanwhile, the 'will-he-won't-he' saga over Trump possibly firing Federal Reserve Chair Jerome Powell rumbles on.
U.S. Treasury Secretary Scott Bessent said on Monday the entire Federal Reserve needed to be examined as an institution and whether it had been successful, further exacerbating worries about the independence of the U.S. central bank.
Key developments that could influence markets on Tuesday:
Earnings: SAP, UniCredit, Julius Baer
Trying to keep up with the latest tariff news?
Our new daily news digest offers a rundown of the top market-moving headlines impacting global trade. Sign up for Tariff Watch here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Swinney to press Trump on Scotch whisky tariffs exemption
Swinney to press Trump on Scotch whisky tariffs exemption

The Independent

time23 minutes ago

  • The Independent

Swinney to press Trump on Scotch whisky tariffs exemption

Scotland's First Minister has vowed to press President Donald Trump to exempt Scotch whisky from US trade tariffs. John Swinney said the 'uniqueness' of whisky made in Scotland justified the exemption from the 10% tariff applied on UK exports into the US. The First Minister, who is due to hold talks with Mr Trump during his ongoing visit to Scotland, said the tariffs were currently costing the local whisky industry £4 million a week. 'Tariffs are very important for the Scottish economy and obviously scotch whisky is a unique product,' he told BBC Breakfast. 'It can only be produced in Scotland. It's not a product that can be produced in any other part of the world. So there's a uniqueness about that, which I think means there is a case for it to be taken out of the tariffs arrangement that is now in place. 'Obviously the trade deal with the United States provides a degree of stability for economic connections with the United States, but the application of tariffs is increasing the costs for the Scotch whisky industry. 'So one of my objectives will be to make the case to President Trump that Scotch whisky should be exempted from those tariffs. 'It's a product that is uniquely produced in Scotland, and it's a product that is much welcomed and supported within the United States. And I think there's a really good case for exempting Scotch whisky, and this is an opportunity that I have to put that case to President Trump on behalf of the Scotch whisky industry, which is a significant part of the Scottish economy. 'And the tariffs just now are costing the industry about £4 million each week, so it's a very significant burden on the industry. It would help growth and development within the Scottish economy if we could secure that deal. And, obviously, I'll be using every opportunity I have to try to put that across to President Trump.' Mr Trump's five-day visit to Scotland is largely a private one that has seen the president play golf at his course at Turnberry in Ayrshire ahead of opening a new course at his property in Aberdeenshire on Tuesday. Mr Swinney said the final cost of the policing the visit has yet to be worked out. 'Obviously, we're working very closely with Police Scotland and the Scottish Police Authority about the arrangements for this visit,' he said. 'The security arrangements have gone well since President Trump arrived on Friday, and that's as it should be, because we've got an obligation to make sure that when we have major international visitors, when they come to Scotland, that they are protected and able to go about their activities. Pressed to reveal the bill, Mr Swinney added: 'All of that will be worked out and we'll address that with Police Scotland and the Scottish Police Authority, and we're talking to the United Kingdom government about these questions, but it's important that we have a secure policing operation. 'It's also important that members of the public who wish to express their point of view, who want to protest about the visit or about other issues, are able to go about their exercise of their democratic right to protest. That's exactly what they've been able to do since Friday, and that's the way it should be.'

Citroen's new SUV is £7k cheaper than a VW Tiguan
Citroen's new SUV is £7k cheaper than a VW Tiguan

Auto Express

time23 minutes ago

  • Auto Express

Citroen's new SUV is £7k cheaper than a VW Tiguan

Citroen has announced pricing for its new C5 Aircross with the flagship SUV set to start from just over £30,000. The C5 Aircross will continue Citroen's 'multi-energy' platform strategy - meaning it'll be offered with a petrol hybrid and all-electric power. The Citroen C5 Aircross comes in the three trim levels you'd find across in Citroen's model range. With the 'Hybrid 145' powertrain, the C5 Aircross starts in You! guise from £30,495, before going up to £33,135 for the mid-range 'Plus' and £35,775 for the top-spec 'Max'. Choose the all-electric version of any of those trim levels and you'll pay an extra £3,570. Citroen says orders are open now with the new car arriving in showrooms from October, although if you can't wait until then you can buy a used Citroen C5 Aircross through our Find a Car service. Advertisement - Article continues below Inside the C5 Aircross you'll find a 10-inch driver's display and a 13-inch 'Waterfall' portrait-oriented touchscreen in the middle of the dash - no matter which trim you go for. The mid-spec Plus gets a 180-degree camera and 19-inch alloy wheels instead of the You! 18-inch rims, while top-spec Max adds adaptive cruise control, dual-zone air-conditioning, matrix LED headlights with adaptive high beams and a 360-degree exterior cameraOnly the top-spec e-C5 Aircross gets a heat pump as standard. The sole petrol engine is the 143bhp 1.2-litre hybrid, while the e-C5 Aicross comes with a 211bhp electric motor and a 73kWh battery that provides 323 miles of range. A 97kWh battery alternative will arrive soon which will increase power to 228bhp and a range of 423 miles, and a plug-in hybrid will also come at a later date. Our dealer network has 1,000s of great value new cars in stock and available now right across the UK. Find your new car… Find a car with the experts Hyundai slashes prices across its entire EV range Hyundai slashes prices across its entire EV range Korean brand acts swiftly to cut prices on all its electric cars, amid confusion over Government's grant scheme Congestion Charge EV exemption removal to generate over £75million per year Congestion Charge EV exemption removal to generate over £75million per year TfL is planning to raise the Congestion Charge to £18, and EV drivers will have to pay too Dacia's baby EV due in 12 months with a tiny £15k price tag Dacia's baby EV due in 12 months with a tiny £15k price tag Dacia's new model will be developed in double-quick time, and it'll be built in Europe to avoid China tariffs

UK's Oxford Biomedica sees first-half sales surging on strong order book
UK's Oxford Biomedica sees first-half sales surging on strong order book

Reuters

time24 minutes ago

  • Reuters

UK's Oxford Biomedica sees first-half sales surging on strong order book

July 28 (Reuters) - British cell and gene therapy manufacturer Oxford Biomedica (OXB.L), opens new tab said on Monday it expects first-half sales to jump around 40% as orders remain strong, and maintained its annual forecasts for revenue and profit. Oxford Biomedica, which provides contracting services to pharmaceutical firms, said it signed new contracts worth about 149 million pounds ($200 million) in the six months ended June 30, more than doubling from a year earlier, giving it confidence in both its full-year and medium-term targets. Demand was particularly strong in late-stage programmes, allowing it to go ahead with planned capacity expansions to accommodate demand, the firm said. Its shares rose more than 4% in early trading in London. "With robust fundamentals in place and clear visibility into the second half of the year, we remain confident in our ability to deliver our full year guidance and achieve sustainable growth in 2025 and beyond," CEO Frank Mathias said. For the first half, Oxford Biomedica expects to report revenues of about 70 million pounds to 73 million pounds, higher by 38% to 44% from a year earlier. Analysts at JPMorgan said at the midpoint of 71.5 million pounds, revenue was 3% ahead of consensus. The company, spun off from the University of Oxford in 1995, continues to expect full-year revenue of 160 million pounds to 170 million pounds, with core profit in low-single-digit numbers, against a loss, opens new tab of 15.3 million pounds last year. ($1 = 0.7448 pounds)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store